Edward Wilson Grandin, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart-Assist Devices | 16 | 2022 | 1196 | 3.140 |
Why?
|
Extracorporeal Membrane Oxygenation | 9 | 2023 | 1356 | 2.540 |
Why?
|
Heart Failure | 22 | 2023 | 10905 | 1.490 |
Why?
|
Ventricular Dysfunction, Right | 7 | 2022 | 582 | 1.330 |
Why?
|
Shock, Cardiogenic | 7 | 2023 | 688 | 0.840 |
Why?
|
Heart Ventricles | 7 | 2022 | 3820 | 0.690 |
Why?
|
Respiratory Insufficiency | 2 | 2023 | 1199 | 0.610 |
Why?
|
Registries | 10 | 2023 | 8090 | 0.600 |
Why?
|
Blood Coagulation | 2 | 2022 | 1127 | 0.580 |
Why?
|
Phosphodiesterase 5 Inhibitors | 3 | 2022 | 101 | 0.540 |
Why?
|
Hemorrhage | 3 | 2022 | 3461 | 0.530 |
Why?
|
Pulsatile Flow | 1 | 2016 | 332 | 0.510 |
Why?
|
Heparin | 1 | 2021 | 1637 | 0.480 |
Why?
|
Drug Substitution | 1 | 2015 | 281 | 0.430 |
Why?
|
Cyclic Nucleotide Phosphodiesterases, Type 5 | 2 | 2022 | 34 | 0.390 |
Why?
|
Thrombosis | 2 | 2021 | 2968 | 0.380 |
Why?
|
Pulmonary Artery | 2 | 2016 | 1912 | 0.380 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2016 | 531 | 0.370 |
Why?
|
Galectin 3 | 1 | 2011 | 227 | 0.360 |
Why?
|
Anticoagulants | 2 | 2022 | 4599 | 0.350 |
Why?
|
Survival Rate | 4 | 2020 | 12781 | 0.340 |
Why?
|
Oligopeptides | 1 | 2014 | 1178 | 0.340 |
Why?
|
Cardiovascular Agents | 1 | 2015 | 850 | 0.330 |
Why?
|
Myocardial Infarction | 4 | 2023 | 11728 | 0.280 |
Why?
|
Retrospective Studies | 19 | 2023 | 77426 | 0.270 |
Why?
|
Drug Prescriptions | 1 | 2015 | 1637 | 0.270 |
Why?
|
Obesity, Morbid | 1 | 2016 | 1213 | 0.260 |
Why?
|
Guideline Adherence | 1 | 2015 | 2266 | 0.250 |
Why?
|
Quality Assurance, Health Care | 1 | 2015 | 2211 | 0.250 |
Why?
|
Prosthesis Implantation | 2 | 2020 | 642 | 0.240 |
Why?
|
Hospitals | 1 | 2015 | 3952 | 0.200 |
Why?
|
Ventricular Function, Right | 2 | 2022 | 592 | 0.190 |
Why?
|
Hospital Mortality | 4 | 2023 | 5316 | 0.190 |
Why?
|
Intra-Aortic Balloon Pumping | 1 | 2022 | 219 | 0.190 |
Why?
|
Factor Xa | 1 | 2021 | 162 | 0.190 |
Why?
|
Middle Aged | 18 | 2023 | 213367 | 0.180 |
Why?
|
Humans | 33 | 2023 | 744220 | 0.170 |
Why?
|
Acute Coronary Syndrome | 1 | 2011 | 2337 | 0.160 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 7281 | 0.160 |
Why?
|
Adult | 16 | 2023 | 214035 | 0.160 |
Why?
|
Catheterization | 1 | 2023 | 1469 | 0.150 |
Why?
|
Erythrocyte Transfusion | 1 | 2021 | 565 | 0.140 |
Why?
|
Multiple Myeloma | 1 | 2014 | 5180 | 0.140 |
Why?
|
Male | 20 | 2023 | 350027 | 0.140 |
Why?
|
Databases, Factual | 3 | 2021 | 7730 | 0.130 |
Why?
|
Myocarditis | 1 | 2023 | 771 | 0.130 |
Why?
|
Female | 20 | 2023 | 380197 | 0.130 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2021 | 924 | 0.130 |
Why?
|
Cardiac Resynchronization Therapy Devices | 1 | 2016 | 124 | 0.130 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2016 | 264 | 0.130 |
Why?
|
Ventricular Function | 1 | 2016 | 416 | 0.120 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 1518 | 0.120 |
Why?
|
Transplants | 1 | 2017 | 209 | 0.120 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12355 | 0.120 |
Why?
|
Hemodynamics | 3 | 2022 | 4199 | 0.120 |
Why?
|
Equipment Failure | 1 | 2016 | 579 | 0.120 |
Why?
|
Vascular Resistance | 1 | 2016 | 937 | 0.120 |
Why?
|
Treatment Outcome | 8 | 2022 | 63119 | 0.110 |
Why?
|
Cardiology | 1 | 2023 | 1668 | 0.100 |
Why?
|
Incidence | 5 | 2021 | 20945 | 0.100 |
Why?
|
Risk Factors | 8 | 2023 | 72280 | 0.100 |
Why?
|
Hypertension, Pulmonary | 1 | 2022 | 1536 | 0.100 |
Why?
|
Aged | 11 | 2021 | 163253 | 0.090 |
Why?
|
Heptanoic Acids | 1 | 2011 | 343 | 0.090 |
Why?
|
Pravastatin | 1 | 2011 | 395 | 0.090 |
Why?
|
Insurance, Health | 1 | 2021 | 2494 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2018 | 1955 | 0.080 |
Why?
|
Stroke Volume | 2 | 2021 | 5008 | 0.080 |
Why?
|
Medicaid | 1 | 2020 | 2736 | 0.070 |
Why?
|
Follow-Up Studies | 3 | 2021 | 39045 | 0.070 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2017 | 2072 | 0.070 |
Why?
|
United States | 5 | 2021 | 69867 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6535 | 0.070 |
Why?
|
Heart Rate | 1 | 2016 | 4092 | 0.060 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3669 | 0.060 |
Why?
|
Overweight | 1 | 2016 | 2370 | 0.060 |
Why?
|
Pyrroles | 1 | 2011 | 1143 | 0.060 |
Why?
|
Blood Transfusion | 2 | 2022 | 1296 | 0.060 |
Why?
|
Heart Transplantation | 1 | 2017 | 3123 | 0.060 |
Why?
|
Medicare | 1 | 2021 | 6566 | 0.060 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2017 | 2208 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12244 | 0.050 |
Why?
|
Cardiac Surgical Procedures | 1 | 2017 | 3533 | 0.050 |
Why?
|
Comorbidity | 1 | 2016 | 10387 | 0.050 |
Why?
|
Kidney Transplantation | 1 | 2017 | 4251 | 0.050 |
Why?
|
Ultrasonography | 1 | 2014 | 5982 | 0.050 |
Why?
|
Cohort Studies | 2 | 2021 | 40559 | 0.050 |
Why?
|
Time Factors | 3 | 2018 | 40063 | 0.050 |
Why?
|
Stroke | 1 | 2022 | 9981 | 0.040 |
Why?
|
Hemostasis | 1 | 2022 | 458 | 0.040 |
Why?
|
Body Mass Index | 1 | 2016 | 12718 | 0.040 |
Why?
|
Pilot Projects | 1 | 2011 | 8321 | 0.040 |
Why?
|
Renin-Angiotensin System | 1 | 2021 | 759 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3256 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15161 | 0.040 |
Why?
|
Heart Function Tests | 1 | 2016 | 330 | 0.030 |
Why?
|
Fellowships and Scholarships | 1 | 2023 | 1076 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2011 | 9960 | 0.030 |
Why?
|
Propensity Score | 1 | 2021 | 1781 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 2958 | 0.030 |
Why?
|
Obesity | 1 | 2016 | 12742 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2011 | 21752 | 0.030 |
Why?
|
Prospective Studies | 2 | 2022 | 53280 | 0.030 |
Why?
|
Hospitalization | 2 | 2023 | 10262 | 0.030 |
Why?
|
Aged, 80 and over | 1 | 2016 | 57768 | 0.020 |
Why?
|
Prosthesis Design | 1 | 2018 | 2110 | 0.020 |
Why?
|
Prognosis | 1 | 2011 | 29050 | 0.020 |
Why?
|
Prostheses and Implants | 1 | 2017 | 1387 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10250 | 0.020 |
Why?
|
Recovery of Function | 1 | 2018 | 2925 | 0.020 |
Why?
|
Patient Selection | 1 | 2018 | 4216 | 0.020 |
Why?
|
Echocardiography | 1 | 2018 | 5103 | 0.020 |
Why?
|
Quality of Life | 1 | 2023 | 12805 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15070 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2018 | 19907 | 0.010 |
Why?
|
Risk Assessment | 1 | 2018 | 23337 | 0.010 |
Why?
|
Young Adult | 1 | 2017 | 56436 | 0.010 |
Why?
|